Global Chronic Kidney Disease Market – Overview
Market Research Future (MRFR) expects the Global Chronic Kidney Disease Market to exhibit a robust 5.2% CAGR over the forecast period from 2017 to 2023. The global chronic kidney disease market is mainly driven by the growing prevalence of hypertension, i.e. high blood pressure, and diabetes among the geriatric population around the world, which is growing at a rapid rate due to advances in medical technology, making longer lifetimes not just possible but normal.
Rising prevalence of hypertension is likely to be the major driving factor for the global chronic kidney disease market over the forecast period.
Rising prevalence of dietary factors enabling hypertension, including high consumption of heavy, red meats, heavy consumption of tobacco through cigarettes, and the increasingly sedentary lifestyles of the modern urban population have been responsible for the growing prevalence of hypertension in the developed world.
In developing regions as well, the prevalence of hypertension is growing due to the increasing adoption of Western dietary and lifestyle patterns. The growing consumption of fast food in the emerging Asia Pacific regions has led to growing prevalence of hypertension, which is a key cause of chronic kidney disease.
GET PREMIUM SAMPLE REPORT @ https://www.marketresearchfuture.com/sample_request/5744
Key players in the global chronic kidney disease market include Abbott Laboratories, Sysmex, F. Hoffman-La Roche Ltd., URIT Medical, ARKRAY, 77 Elektronika, Teva Pharmaceutical Industries Ltd., AstraZeneca PLC, Sanofi SA, AbbVie Inc., Kissei Pharmaceutical Co. Ltd., GSK plc, Pfizer Inc., Amgen Inc., Randox Laboratories, OPTI Medical, Nova Biomedical, ACON Laboratories Inc., Beckman Coulter, and Siemens Healthineers.
Global Chronic Kidney Disease Market – Segmentation
The global chronic kidney disease market is segmented on the basis of diagnosis, treatment, indication, end user, and region.
On the basis of diagnosis, the global chronic kidney disease market is segmented into blood test, urine test, imaging test, and kidney biopsy.
On the basis of treatment, the market is segmented into drugs, dialysis, and kidney transplant. Drugs used for the treatment of chronic kidney disease include ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, beta-blockers, and erythropoiesis-stimulating agents.
On the basis of indication, the chronic kidney disease market is segmented into Type 1 or Type 2 diabetes, high blood pressure, polycystic kidney disease, and others.
On the basis of end user, the global chronic kidney disease market is segmented into hospitals and clinics, diagnostic centers, and others.
Detailed Growth Analysis
Diabetes is also likely to grow in prevalence over the forecast period in the developed as well as developing world. The rising awareness about diabetes in the developing world has been crucial for increasing awareness about its connection with chronic kidney disease and the risks of the same for the patient. Chronic kidney disease affects the elderly more than the younger demographics, although certain dietary and lifestyle factors can certainly increase the risk of chronic kidney disease in younger populations as well.
The increasing number of biopsy procedures for diagnostic purposes in the global chronic kidney disease market is likely to be a major driver for the global market over the forecast period. The demand for new techniques of diagnosing kidney disease is also likely to drive research and development activities in the global chronic kidney disease market.
BROWSE PREMIUM RESEARCH REPORT DETAILS @ https://www.marketresearchfuture.com/reports/chronic-kidney-disease-market-5744
Global Chronic Kidney Disease Market – Regional Analysis
The global chronic kidney disease market is segmented into Americas, Europe, Asia Pacific, and the Middle East.
The Americas segment is likely to be the major regional market for chronic kidney disease treatment and diagnostic services over the forecast period due to the growing prevalence of kidney disease in the geriatric population in countries such as the U.S. and Canada.
The geriatric demographic is a significant portion of the population in these countries and is likely to comprise a major part of the region’s healthcare expenditure over the forecast period. This is likely to drive the chronic kidney disease market in the U.S. and Canada, as the prevalence of chronic kidney disease is higher in the geriatric demographic than in the rest of the population.
Europe accounts for around 25% of the global chronic kidney disease market, with Asia Pacific following Europe closely. Europe is likely to remain an important market for chronic kidney disease research and product development due to the growing geriatric population in developed Western European countries such as Germany, France, Belgium, the Netherlands, and the UK and the high disposable income of consumers in these regions.
A new study published in Lancet in February 2019 found that chronic kidney disease is deadlier in India than HIV/AIDS in terms of premature deaths of adults and took more than 135,000 lives in 2015. It is estimated to be the third deadliest disease over the next two decades, behind only heart disease and brain strokes. This illustrates the potential of the chronic kidney disease market in India, a key Southeast Asian market.
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar